BERLIN, June 11, 2021 (GLOBE NEWSWIRE) — atai Life Sciences B.V. (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the commencement of a proposed underwritten initial public offering of 14,286,000 of its common shares. All common shares to be sold in the proposed offering will be sold by atai. The underwriters of the…


Previous articleLSD and the Anarchic Brain
Next articleAtai Targets $2.3bn Valuation in Nasdaq IPO